key: cord-0901948-h0kdahk3
authors: ALMuhizi, Faisal; Fein, Michael; Gabrielli, Sofianne; Gilbert, Louise; Tsoukas, Christos; Ben-Shoshan, Moshe; Copaescu, Ana M.; Isabwe, Ghislaine A.C
title: Allergic Reactions to the COVID-19 vaccine (ARCOV) study: the McGill University Health Center (MUHC) experience
date: 2022-05-21
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2022.05.014
sha: 8dbc78ecc271655b79405b0c1494bd0c5d019302
doc_id: 901948
cord_uid: h0kdahk3

Background : mRNA-COVID-19 vaccines have been associated with allergic reactions. A history of anaphylaxis has been suggested as a risk factor for such reactions. Polyethylene glycol (PEG) has been proposed as a possible culprit allergen. Objective : To investigate possible PEG or polysorbate allergy among patients reporting prior reactions to COVID-19 vaccines or PEG, and to report their subsequent tolerance of COVID-19 vaccines. Methods : From January 1 st to October 31 st, 2021, adult patients referred to the MUHC allergy clinics who were considered at risk of anaphylaxis were prospectively recruited. The entry criteria were any documented history of reaction to a COVID-19 vaccine or reported allergy to PEG or polysorbate. Evaluated patients underwent skin-prick-testing (SPT) with PEG and polysorbate. Following SPT, placebo-controlled vaccine challenges were carried out. Results : Of the 44 patients recruited, 40 (90.1%) had reacted to the first vaccine dose, 18 (45%) of them had anaphylactic reaction. All patients underwent SPT and 5 (11.3%) had a positive test. Thirty-nine patients (88.6%) underwent COVID-19 vaccine challenge at the allergy clinic. The majority tolerated the vaccine, 18 (40.1%) received a single full-dose, 20 (45.4%) 2-split-doses and 6 (13.6%) using a graded dosing protocol. Two out of the 40 patients who reacted to 1 st dose, had immediate non-severe allergic reactions to the second dose. Conclusion : In this cohort of patients with a history of anaphylaxis and increased risk of allergic reactions to the COVID-19 vaccines, following allergist evaluation, including negative PEG skin testing, the vaccine was safely administered without any serious adverse events.

The authors certify that they have (collectively) personally written at least 90 percent of the manuscript. This manuscript has not been published previously in print/electronic format.

FA performed the literature review and wrote the manuscript text with support from MF, AC and GI. FA, MF, AC, and GI recruited patients, contributed to the vaccination protocol, and performed the follow-up survey. All authors reviewed the manuscript and made a substantial, direct, and intellectual contribution to the work. All authors approved the manuscript for publication.

Background mRNA-COVID-19 vaccines have been associated with allergic reactions. A history of anaphylaxis has been suggested as a risk factor for such reactions. Polyethylene glycol (PEG) has been proposed as a possible culprit allergen.

To investigate possible PEG or polysorbate allergy among patients reporting prior reactions to COVID-19 vaccines or PEG, and to report their subsequent tolerance of COVID-19 vaccines.

From January 1 st to October 31 st , 2021, adult patients referred to the MUHC allergy clinics who were considered at risk of anaphylaxis were prospectively recruited. The entry criteria were any documented history of reaction to a COVID-19 vaccine or reported allergy to PEG or polysorbate. Evaluated patients underwent skin-prick-testing (SPT) with PEG and polysorbate. Following SPT, placebo-controlled vaccine challenges were carried out.

Of the 44 patients recruited, 40 (90.1%) had reacted to the first vaccine dose, 18 (45%) of them had anaphylactic reaction. All patients underwent SPT and 5 (11.3%) had a positive test. Thirty-nine patients (88.6%) underwent COVID-19 vaccine challenge at the allergy clinic. The majority tolerated the vaccine, 18 (40.1%) received a single full-dose, 20 (45.4%) 2-split-doses and 6 (13.6%) using a graded dosing protocol. Two

The coronavirus disease 2019 (COVID-19) pandemic presents an enormous challenge for public health and clinicians globally. Using different platform technologies, vaccines have been developed and approved by various governmental agencies to help fight the COVID-19 disease. Vaccines, in general, carry the risk of anaphylaxis at a rate of 1.31 cases/1 million doses (1) . The newly manufactured mRNA vaccines are associated with allergic reactions at the rate of 2.5-7.91 cases/1 million doses (2) (3) (4) . The causal agents for the allergic reactions to mRNA COVID-19 vaccines are not clearly determined, but the excipient polyethylene glycol (PEG) 2,000 has recently gained worldwide attention (5) . Messenger ribonucleic acid (mRNA) vaccines manufactured by Pfizer-BioNTech and Moderna contain PEG 2,000.

The viral vector vaccines manufactured by AstraZeneca and Johnson & Johnson contain excipients such as polysorbate 80. PEG is a hydrophilic polymer with different molecular weights, widely used as an excipient in medications and skin care products (6) . The rate of true allergic reactions to PEG is not known but it is likely to be under-reported (6) . Currently, there is no consensus about the utility of the skin prick testing (SPT) to PEG in determining patients at risk or who may have reacted to the mRNA COVID-19 vaccines.

At the beginning of the vaccination campaign, there have been early reports of anaphylaxis following vaccination in some patients with previous history of anaphylaxis and at that time, it was not yet understood whether or not patients with a history of anaphylaxis are at higher risk of severe hypersensitivity reaction to COVID-19 vaccination (7, 8) . This led to the initial recommendation of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to exclude from vaccination any person with a history of food, drug, or vaccine anaphylaxis. While this recommendation has been amended, there are recent publications describing COVID-19 vaccine reactions in patients with history of self-reported allergic reactions. Patients that have reported anaphylaxis to the vaccine are more likely to be women with prior history of allergic reactions (7) (8) (9) . The overall recommendation for the reported allergy symptoms after receiving the COVID-19 vaccines did not impede the completion of the 2-dose vaccine in patients with prior history of allergies, supporting the overall safety of mRNA COVID-19 vaccine (10-13).

The primary outcome of our study was to investigate possible PEG or polysorbate allergy among patients reporting prior reactions to COVID-19 vaccines or PEG. The secondary outcomes were (1) to determine if patients with a prior history of adverse reactions to the excipients found in the COVID-19 vaccines (i.e., PEG or PEG chemically related compounds) can safely tolerate one of the COVID-19 vaccines; (2) to determine if patients with adverse reaction to their first COVID-19 vaccine may safely tolerate the second dose; and (3) to determine the number of confirmed allergies to excipients including PEG, polysorbate 80, and Cremophor EL (PEG 35).

This is a prospective study conducted from January 1 st 2021 to October 31 st 2021. All adult patients who were referred to the MUHC allergy clinic with a history of anaphylaxis to medications, vaccines, food or Hymenoptera venom, suspected PEG or polysorbate allergy, or a prior hypersensitivity reaction to COVID-19 vaccination were approached for potential participation in the study. However, we only report the patients with allergic reaction to the COVID-19

vaccine or with history of reaction to PEG related compounds. The inclusion criteria were any documented history of anaphylaxis (involvement of two organs or more with abnormal vital signs), and/or suspected past reactions or documented reactions to PEG, or the actual COVID-19 vaccine (Cremophor EL), PEG 300, PEG 3,000 , Polysorbate 80, and high MW PEG 20,000 (6) . PEG 3,350 (50% wt./vol) (lax-a-day) was also used for skin prick test. The dilutions were performed as per previously published protocols (6) . SPT was performed on the forearm with a positive control of histamine 10 mg/ml and a negative control of normal saline, with results recorded 15 minutes after the test. A positive reaction was defined as a recorded wheal size measuring 3 mm in diameter or more compared to the negative control (normal saline). Excipient skin testing alone was used in our cohort considering the global shortage of vaccine supply during the pandemic.

Challenge. Following SPT, the patients underwent a single-blinded placebo-controlled challenge to either Lax-a-day (oral laxative containing PEG 3,350), before the availability of the vaccine in our vaccine provocation unit or one of the mRNA COVID-19 vaccines (1-or 2-split doses or graded dosing).

The placebo consisted of Normal Saline 0.5 ml. It was administered intramuscularly to the patient in the deltoid muscle, prior to the actual vaccine dose, followed by a 30 minute observation period before administering the vaccine. Patients were observed for 30 minutes between doses and for one hour after the last dose. If the challenge was negative, the patients were instructed to receive the vaccines or their subsequent doses in a vaccination center. In a sub-cohort of ARCOV study, patients who underwent graded dosing administration are reported in another published article (14) .

None of the patients received AstraZeneca in the allergy clinic due to unavailability.

One-week survey. For the patients that received the COVID-19 vaccine, the presence or absence of a non-immediate reaction to the vaccine was assessed after one week by telephone or an electronic survey. Data analysis. All statistical analyses were done using R version 4.1.0 (R Core Team [2013]; R: A language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria) and figures were generated using Biorender program. The patient's demographics and clinical characteristics were described by percentage for categorical data and by median [interquartile range (IQR)] for continuous data. All variables, except age, were dichotomized.

Among the 129 patients that met the enrollment criteria, 44 reported hypersensitivity reaction to COVID-19 vaccine or PEG related compounds, 39 (88.7%) were female (median age 55.5 years) and the majority were Caucasian (N=35, 79.5%) ( Table 1 ). The history of anaphylaxis was reported in the context of reactions to the COVID-19 vaccines (N=40/44, 91%), PEG or Polysorbate (N=4/44, 9%). Anaphylaxis was defined using the Brighton (N=28, 63.6%) and the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria (N=18, 41%); 64.2% of the patients diagnosed with anaphylaxis according to the Brighton criteria also met anaphylaxis criteria according to the NIAID (15, 16) (Table 2) . Six patients underwent graded dosing to the second dose in the allergy unit. They reported immediate pruritus (N=6), hives (N=6), angioedema (N=6), and difficulty breathing (N=2)

following the first dose of the COVID-19 vaccine.

All 44 patients underwent SPT to PEG chemically related compounds and two (5.9%) had immediate positive SPT (Table 3) . Three (6.8%) patients had delayed positive SPT to PEG chemically related compounds (3-6 hours after SPT in the clinic); In our cohort, no patients showed positive reactivity to SPT for both polysorbate 80 and PEGs.

Following the SPT to PEG chemically related compounds, 18 (41%) patients underwent oral challenge to PEG 3,350, before we had access to the COVID-19 vaccine for administration in the allergy clinic.

Among the 18 patients challenged to oral PEG 3350 in the form of laxative, one patient presented with hives and angioedema; this patient had immediate positive skin testing to PEG 3350 and PEG 20,000 (eFigure 1). She received AstraZeneca vaccine safely. Patients with a negative PEG 3,350 challenge were safely vaccinated in the vaccination center using Pfizer-BioNTech (N= 1), Moderna (N=1) or AstraZeneca vaccines (N= 2) ( Table 4) .

Among the 4 patients with history of reaction to PEG chemically related compounds, one was defined as level 1 (N=1, 25%), two as level 2 (N=2, 50%) and one as level 3 Brighton classification (N=1, 25%).

Two patients (N=2, 50%) had immediate positive skin testing to PEG 3350 and PEG 20,000. All the patients tolerated the COVID-19 vaccine as single full dose (N=2, 50%) or 2 split doses (N=2, 50%) (Table 5) . (Table 5) .

Two (4.5%) patients experienced mild symptoms during COVID-19 vaccine graded dosing. One patient reacted to first dose of Moderna COVID-19 vaccine with immediate hives and subjective throat tightness.

Skin testing was positive for Cremophor EL (PEG 35), and they underwent graded dosing to the second dose of Moderna mRNA-1273 vaccine without any premedication. She did not report any reaction after placebo administration. During the first split dose of 0.05 ml, she reported subjective pruritus. The pruritus worsened after the second split dose of 0.05 ml, so she was given cetirizine 20 mg. Her symptoms improved after 15 minutes, then she received the 3 rd and 4 th split doses that were well tolerated. The other patient reacted to first dose of Pfizer-BioNTech COVID-19 vaccine with immediate hives, bronchospasm, and drowsiness. Skin testing to PEG was negative and she had graded dosing to Pfizer-BioNTech vaccine. There was no reaction following the administration of 2 placebo doses, however, 10 minutes after her third split dose (0.15 ml) of the vaccine, she reported pruritus and redness over both her hands and arms as well a pressure in the right ear. She was treated with cetirizine 20 mg PO and her symptoms improved within 30 minutes. Two hours after the last dose, she reported pressure in her ears, lightheadedness and her systolic blood pressure dropped from 122 to 101. She was managed with 250 ml of intravenous normal saline with rapid improvement of her symptoms. She did not require epinephrine.

The most common reported side effects were arm tenderness (N=28/44, 63.6%), headache and fatigue (N=10/44, 22.7%), swelling on the lips/face (N=1/44, 2.3%) ( Table 6 ). One patient that had initially reported anaphylaxis to her 1 st dose of Pfizer-BioNTech vaccine (Brighton classification grade 2) and had negative skin testing. She received her 2 nd dose via a graded dosing protocol, then developed an isolated delayed whole-body generalized maculopapular rash which started 1 week after the vaccine injection and was managed with oral desloratadine and mometasone topical cream. This eruption lasted for 3 weeks and was accompanied by a mild skin desquamation but no criteria for severe cutaneous reaction. We believe this was a delayed non-severe generalized maculo-papular eruption secondary to the vaccine.

The mechanism associated with COVID-19 vaccine adverse reactions is not well understood (17) . Our study reveals the safety of COVID-19 vaccine challenges in patients with suspected COVID-19 vaccine allergy. We suspect that a non-IgE mediated or non-immune mechanism was possibly responsible for the first reaction in the majority of patients who tolerated the second dose without issues (8) . There was anxiety caused by the idea of vaccination, as two of our patients had reaction to normal saline .This is in accordance with other studies, where the majority of reactions to the COVID-19 vaccines were considered to be related to either anxiety, vasovagal reaction, or possible vocal cord dysfunction (18) .

We assessed the rate of anaphylaxis using both NIAID (N=18) and Brighton criteria (N=28). These results are in keeping with other studies which suggest that Brighton criteria may over diagnose anaphylaxis (19) . Given the reassuring outcome results in our cohort of patients, we believe that true anaphylactic reaction to the COVID-19 vaccine is rare, similar to other published studies (20) .

Studies suggest that the prevalence of PEG allergy is low (6) . In our cohort, we had two patients with an immediate positive PEG-SPT and/or oral challenge to PEG. Therefore, in patients with suspected multiple allergic reactions to unrelated products, a careful review of the ingredients is paramount. In this cohort involving patients who were considered to be at high risk of developing an allergic reaction to the COVID-19 vaccine, skin prick testing with the excipients such as PEG and its chemically related compounds is not a useful diagnostic tool. However, for patients with a concerning history of a reported reaction to PEG, the skin testing was useful in confirming the evidence of sensitization to PEG (21, 22) .

Seventeen patients with suspicion of PEG hypersensitivity underwent PEG skin testing, which was negative, and subsequently had negative challenges to PEG 3,350. Thus, we report a 100% negative predictive value of PEG skin testing in this small cohort. It has been reported in a recent study that patients with confirmed sensitization to PEG tolerated mRNA COVID-19 vaccines and that this tolerance could be due to the small amount of PEG 2,000 in the mRNA vaccine (23) . We only had one patient who had a positive SPT to PEG and underwent a challenge to PEG 3,350 (lax-a-day), which was positive. As expected from other published data, our cohort showed that patients who have an immediate positive SPT to any low MW PEG, will also be positive to PEG with higher MW (6). This is also described in a paper published by Bruusgaard-Mouritsen et al. (6) where the skin testing with different PEG molecular weights had good reproducibility among their cohort. We did not have any evidence of cross-sensitization among PEGs or polysorbate 80 in contrary of Bruusgaard-Mouritsen et al (6) findings, however, a larger study including patients with definite sensitization to PEG is needed to determine the usefulness of the PEG SPT to predict COVID-19 vaccine hypersensitivity.

In patients with positive delayed results, it is difficult to determine the significance of the SPT to PEG chemically related compounds. Allergic contact dermatitis to PEG has been reported and it is typically diagnosed through patch testing. Delayed skin prick testing may yield similar results as the primed T cells may need longer time to be reactivated (24). In our cohort, there were two patients who had delayed positive SPT to lower MW PEG but negative to high MW PEG.

The placebo-controlled challenge protocol was an important tool allowing the exclusion of false positive reactions with non-allergic subjective symptoms, mostly related to anxiety. The outcomes reported upon the one-week follow-up survey bring reassurance and confirm the absence of delayed adverse reactions to the COVID-19 vaccines. Other non-severe delayed reactions such as cutaneous events following COVID-19 vaccination are generally minor and self-limited and should not discourage subsequent vaccination (25) .

. This study is limited by the small single center cohort with limited history information regarding the initial reported adverse reactions to the COVID-19 vaccine. Also, the majority of the recruited patients had reported mild to moderate reactions and no severe anaphylaxis cases were re-challenged with the COVID-19 vaccine.

This study was conducted during the time of uncertainty about the usefulness of PEG skin testing in the management of suspected allergic reaction to the COVID-19 vaccine. International guidelines have provided evolving recommendations since the beginning of the vaccination campaign regarding the vaccination of high-risk patients, and we expect recommendations may be updated with further information.

Our study adds to the current existing evidence that PEG testing is not required when assessing for allergy to the COVID19 vaccine. In our cohort of patients with a history of PEG allergy and/or prior reported allergic reaction to a COVID-19 vaccine, following allergist evaluation, the vaccine administration was safe and not associated with severe adverse events. Severe adverse reactions to the COVID-19 vaccines are rare events, and most patients that present a reaction to the first dose are not precluded from revaccination with a second dose, either by challenge or graded dosing. Detailed history can help guide patient risk stratification based on the reported reaction, the clinician assessment, and the availability of 

3 (6.8%) 4 (9.1%) 4 (9.1%) 5 (11.4%) 2 (4.5%) 2 (4.5%) (1) acute onset with involvement of skin and/or mucosal tissue and either (a) respiratory compromise or (b) reduced blood pressure or associated symptoms of end organ dysfunction; (2) 2 or more of the following occur after exposure to a likely allergen for that patient: (a) involvement of skin or mucosal tissue, (b) respiratory compromise, (c) reduced blood pressure or associated symptoms, or (d) persistent gastrointestinal symptoms; and (3) reduced blood pressure after exposure to a known allergen for that patient.

Latency: time between the reaction and the allergy evaluation -Single full dose -Two divided doses -Graded dosing 0 0 2 (5%) 0 0 0 *The Brighton Collaboration case definition uses combinations of symptoms to define levels of diagnostic certainty. Brighton level 1 represents the highest level of diagnostic certainty that a reported case represents anaphylaxis; levels 2 and 3 are successively lower levels of diagnostic certainty; level 4 is a case reported as anaphylaxis but that does not meet the Brighton Collaboration case definition; and level 5 is a case that was neither reported as anaphylaxis nor meets the case definition. This study considered Brighton levels 1 or 2 anaphylaxis cases.

**NIAID/FAAN clinical criteria for the diagnosis of anaphylaxis must meet 1 of the following criteria: (1) acute onset with involvement of skin and/or mucosal tissue and either (a) respiratory compromise or (b) reduced blood pressure or associated symptoms of end organ dysfunction; (2) 2 or more of the following occur after exposure to a likely allergen for that patient: (a) involvement of skin or mucosal tissue, (b) respiratory compromise, (c) reduced blood pressure or associated symptoms, or (d) persistent gastrointestinal symptoms; and (3) reduced blood pressure after exposure to a known allergen for that patient.

***immediate reaction: within the first hour after receiving the vaccine, the patients reported urticaria angioedema and/or throat tightness and/or bronchospasm and/or drowsiness. ****delayed reaction: after 1 hour from receiving the vaccine the patient reported urticaria angioedema and/or maculopapular rash.

NIAID/FAAN: National Institute of Allergy and Infectious Diseases / Food Allergy and Anaphylaxis Network. Table 6 : One-week survey following vaccine challenge.

Risk of anaphylaxis after vaccination in children and adults

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

Optimizing investigation of suspected allergy to polyethylene glycols

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions

Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination

Vaccinating against covid-19 in people who report allergies

An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history

Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper

Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose

Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose! Allergy

Ascertainment Bias in Anaphylaxis Safety Data of COVID-19 Vaccines

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Immediate-type hypersensitivity to polyethylene glycols: a review

Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized

Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

The manuscript has been read and approved by all the authors.The requirements for authorship have been met by each listed author.The authors certify that they have (collectively) personally written at least 90 percent of the manuscript. This manuscript has not been published previously in print/electronic format.

FA performed the literature review and wrote the manuscript text with support from MF, AC and GI. FA, MF, AC, and GI recruited patients, contributed to the vaccination protocol, and performed the follow-up survey. All authors reviewed the manuscript and made a substantial, direct, and intellectual contribution to the work. All authors approved the manuscript for publication.